Drug discovery

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Their mission is to develop better TCR-based cancer immunotherapies, faster and at a fraction of the cost.

Focus: Drug discovery platform 

Team: Federio Paoletti (CEO) and Andrea Mambrini (CTO)

Website: https://exogene.co.uk/ 

Find out more about becoming one of our occupiers and all of the benefits of being at SBC. Contact us today.

Get in touch

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.